Extending the reach of targeted medicine
Celek Pharmaceuticals is addressing the need for new medicines to help patients suffering from cancers that lack effective treatment options. We are focusing on the development of targeted therapies for bladder cancer and acute myeloid leukemia, diseases that are in need of safer and more effective treatments.
Our Science
Celek's lead oncology product, CEL-031, targets cGMP phosphodiesterases in cancer cells to induce selective programmed cell death.